This brand name is authorized in Australia, Japan, New Zealand, UK.
The drug PRO-BANTHINE contains one active pharmaceutical ingredient (API):
1
|
UNII
UX9Z118X9F - PROPANTHELINE BROMIDE
|
|
Propantheline inhibits parasympathetic activity by blocking the action of the neurohormone, acetylcholine, on the neuroeffector cell. This blocking action of propantheline is instrumental in reducing gastric acid secretion and gastrointestinal motor activity. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| PRO-BANTHINE Tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A03AB05 | Propantheline | A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS → A03AB Synthetic anticholinergics, quaternary ammonium compounds |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 1953T |
| GB | Medicines & Healthcare Products Regulatory Agency | 23533 |
| JP | 医薬品医療機器総合機構 | 1231008F1032 |
| NZ | Medicines and Medical Devices Safety Authority | 1753 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.